Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07446855) titled 'Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: AstraZeneca
Condition:
Solid Tumours
Intervention:
Drug: AZD4956
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: February 27, 2026
Target Sample Size: 180
Countries of Recruitment:
United States
To know more, vis...